Long COVID can cause persistent symptoms and substantial disability. Therapeutic plasma exchange (TPE) is being investigated as a possible intervention, but benefit is not established. A randomized trial found no improvement over sham treatment. This article explains the distinction between a proposed mechanism and demonstrated clinical benefit.
Why Do Some Long COVID Patients Have Autoantibodies?
Long COVID can include fatigue, post-exertional malaise, cognitive symptoms, and autonomic dysfunction. Its causes remain under investigation; no single mechanism explains every patient's symptoms. Immune changes, viral persistence, and vascular changes are among the hypotheses being studied.
Specifically:
- Autoantibodies: Researchers are investigating whether immune responses contribute to symptoms in some patients.
- Altered clotting: Observations about clotting and microcirculation are research findings, not proof that plasma exchange improves symptoms.
- Inflammation: Changes in inflammatory markers do not by themselves identify an effective treatment.
TPE removes and replaces plasma, including both potentially harmful and useful circulating proteins. A change in blood measurements does not necessarily translate into better function or quality of life.
What the Randomized Trial Found
A 2025 phase II trial published in Nature Communications randomly assigned 50 people with post-COVID condition to six sessions of TPE or sham plasma exchange, with 90 days of follow-up.
Safety was the primary endpoint. The researchers found no differences between groups in the efficacy outcomes evaluated, including symptoms, function, and quality of life. Similar safety findings in this trial do not make TPE risk-free.
This result does not settle every possible research question, but it does not support presenting TPE as a proven or reliably effective treatment for Long COVID.
How to Interpret Other Research
When considering other reports, distinguish the type of evidence:
- Laboratory findings can generate hypotheses but cannot establish patient benefit.
- Case reports cannot reliably separate treatment effects from natural change, other treatments, or expectations.
- Immunoadsorption and other blood-processing techniques are not the same procedure as TPE; their results cannot be substituted for TPE evidence.
What to Discuss at a Consultation
There is no established test that reliably predicts benefit from TPE for Long COVID. Your clinician can review:
- Your symptoms, functional limitations, and existing diagnoses
- Previous evaluations and treatments, including specialist recommendations
- Medications and medical conditions that could increase procedural risks
- Symptom-directed care, specialist referrals, and research participation
Severe symptoms or unsuccessful prior treatments do not establish that TPE will help. Decisions require an individualized discussion of uncertainty, alternatives, risks, and cost.
Risks and Practical Questions
Before considering any course of treatment, discuss:
- Risks: Low blood pressure, calcium changes, allergic reactions, bleeding, infection, and vascular-access complications.
- Access and monitoring: Purety Clinic uses ultrasound-guided vascular access for every TPE session. Ask about laboratory checks, monitoring, and emergency arrangements.
- Goals and reassessment: Agree on meaningful outcomes and when to stop if there is no benefit or adverse effects occur.
- Costs: Ask about the full proposed course, follow-up expenses, and insurance coverage before proceeding.
Is TPE the Right Choice for You?
TPE for Long COVID remains investigational. A consultation is an opportunity to review evidence and options, not a guarantee of treatment or improvement.
If you're in Santa Barbara, Ventura, Los Angeles, or anywhere in California and are dealing with refractory Long COVID, we'd be glad to evaluate whether therapeutic plasma exchange might be appropriate for your situation. We also offer remote consultations for patients who cannot travel to our Santa Barbara clinic.
